226 related articles for article (PubMed ID: 20635074)
1. [Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts].
Wick W; Weller M
Nervenarzt; 2010 Aug; 81(8):928-30, 932-5. PubMed ID: 20635074
[TBL] [Abstract][Full Text] [Related]
2. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
[TBL] [Abstract][Full Text] [Related]
3. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
van den Bent MJ; Dubbink HJ; Marie Y; Brandes AA; Taphoorn MJ; Wesseling P; Frenay M; Tijssen CC; Lacombe D; Idbaih A; van Marion R; Kros JM; Dinjens WN; Gorlia T; Sanson M
Clin Cancer Res; 2010 Mar; 16(5):1597-604. PubMed ID: 20160062
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach.
Rajmohan KS; Sugur HS; Shwetha SD; Ramesh A; Thennarasu K; Pandey P; Arivazhagan A; Santosh V
J Clin Pathol; 2016 Aug; 69(8):686-94. PubMed ID: 26743027
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
[TBL] [Abstract][Full Text] [Related]
6. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
Vogelbaum MA; Berkey B; Peereboom D; Macdonald D; Giannini C; Suh JH; Jenkins R; Herman J; Brown P; Blumenthal DT; Biggs C; Schultz C; Mehta M
Neuro Oncol; 2009 Apr; 11(2):167-75. PubMed ID: 18779504
[TBL] [Abstract][Full Text] [Related]
8. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
van den Bent MJ; Dubbink HJ; Sanson M; van der Lee-Haarloo CR; Hegi M; Jeuken JW; Ibdaih A; Brandes AA; Taphoorn MJ; Frenay M; Lacombe D; Gorlia T; Dinjens WN; Kros JM
J Clin Oncol; 2009 Dec; 27(35):5881-6. PubMed ID: 19901104
[TBL] [Abstract][Full Text] [Related]
9. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.
Jiang H; Ren X; Cui X; Wang J; Jia W; Zhou Z; Lin S
Neuro Oncol; 2013 Jun; 15(6):775-82. PubMed ID: 23486687
[TBL] [Abstract][Full Text] [Related]
10. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.
Rauscher J; Beschorner R; Gierke M; Bisdas S; Braun C; Ebner FH; Schittenhelm J
J Clin Pathol; 2014 Jul; 67(7):556-61. PubMed ID: 24607494
[TBL] [Abstract][Full Text] [Related]
11. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
Xiong J; Liu Y; Wang Y; Ke RH; Mao Y; Ye ZR
Chin Med J (Engl); 2010 Dec; 123(24):3566-73. PubMed ID: 22166632
[TBL] [Abstract][Full Text] [Related]
12. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
Wiestler B; Capper D; Hovestadt V; Sill M; Jones DT; Hartmann C; Felsberg J; Platten M; Feiden W; Keyvani K; Pfister SM; Wiestler OD; Meyermann R; Reifenberger G; Pietsch T; von Deimling A; Weller M; Wick W
Neuro Oncol; 2014 Dec; 16(12):1630-8. PubMed ID: 25028501
[TBL] [Abstract][Full Text] [Related]
13. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.
Houillier C; Wang X; Kaloshi G; Mokhtari K; Guillevin R; Laffaire J; Paris S; Boisselier B; Idbaih A; Laigle-Donadey F; Hoang-Xuan K; Sanson M; Delattre JY
Neurology; 2010 Oct; 75(17):1560-6. PubMed ID: 20975057
[TBL] [Abstract][Full Text] [Related]
14. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
[TBL] [Abstract][Full Text] [Related]
15. IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
Minniti G; Scaringi C; Arcella A; Lanzetta G; Di Stefano D; Scarpino S; Bozzao A; Pace A; Villani V; Salvati M; Esposito V; Giangaspero F; Enrici RM
J Neurooncol; 2014 Jun; 118(2):377-383. PubMed ID: 24748470
[TBL] [Abstract][Full Text] [Related]
16. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
17. Low-grade and anaplastic oligodendroglioma.
Van Den Bent MJ; Bromberg JE; Buckner J
Handb Clin Neurol; 2016; 134():361-80. PubMed ID: 26948366
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic Glioma: Treatment Approaches in the Era of Molecular Diagnostics.
Ruff MW; Uhm J
Curr Treat Options Oncol; 2018 Oct; 19(12):61. PubMed ID: 30361986
[TBL] [Abstract][Full Text] [Related]
19. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]